Abstract 11776: Lower Body Mass Index is a Risk Factor of Blunted Response to β-Blocker Therapy Using Carvedilol: Insights From J-CHF Study

Introduction: Cardiac cachexia is a strong predictor of a poor clinical outcome in patients with heart failure (HF), whereas the prognosis of obese HF patients is more favorable compared with lean ones, often referred to as “obesity paradox”. However, their underlying mechanisms still remain unknown. The aim of this study was to explore the impact of body mass index (BMI) on patients with HF and reduced ejection fraction (HFrEF) who receive carvedilol therapy in J-CHF study. Methods and Results: J-CHF study was a multicenter, prospective, randomized, stratified trial in which 364 patients with HFrEF (LVEF≤40%) were enrolled and they were assigned to target dose of carvedilol 2.5mg, 5mg, or 20mg daily. In this post-hoc analysis, 360 patients were available for analysis. The study population was divided into L group (BMI<25, n=246) and H group (BMI≥25, n=114) according to the BMI at baseline. The dose allocation and achieved dose of carvedilol were comparable between L and H groups. The time course change o...